Rohit Dhall, MD
Neurology · Phoenix, AZNPI 1699982884
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $22,425 of the $25,525 with a category attached, or 87.9%. 6 manufacturers reported payments, led by Cala Health, Inc. at 33.3% of the total. 2025 is the largest year on record at $8,709, 2.3 times the $3,725 reported in 2020.
Across 17 payments — averaging $1501.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cala Health, Inc.$9K
- AbbVie$7K
- Tanabe Pharma America, Inc.$4K
- Acorda Therapeutics, Inc$4K
- MDD US Operations, LLC$2K
- Teva Pharmaceuticals USA, Inc.$191
Across 287 payments — averaging $2855.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amneal Pharmaceuticals LLC$327K
- Neurocrine Biosciences, Inc.$213K
- Sage Therapeutics, LLC$126K
- AbbVie$53K
- H. Lundbeck A S$31K
- Takeda Pharmaceuticals U.S.A., Inc.$28K
- plus $41K from 3 others
What the payments were for
- Consulting fees$22,42588%
- Speaking & faculty fees$1,7607%
- Travel & lodging$7973%
- Food & beverage$3521%
- Education$1911%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cala Health, Inc. | 3 | $8,500 |
| AbbVie | 9 | $6,949 |
| Tanabe Pharma America, Inc. | 1 | $4,400 |
| Acorda Therapeutics, Inc | 1 | $3,725 |
| MDD US Operations, LLC | 1 | $1,760 |
| Teva Pharmaceuticals USA, Inc. | 2 | $191 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,525 in reported general payments places this provider in the 80th percentile of 388 neurology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammakedImmune Globul G/Gly/Iga Avg 46 | 31 | $449,788 |
| IngrezzaValbenazine Tosylate | 42 | $323,470 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 17 | $169,117 |
| NuplazidPimavanserin Tartrate | 35 | $165,675 |
| RytaryCarbidopa/Levodopa | 138 | $144,278 |
| AustedoDeutetrabenazine | 12 | $88,305 |
| Austedo XrDeutetrabenazine | 16 | $86,931 |
| GocovriAmantadine Hcl | 21 | $51,595 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 293 | $9,859 |
| Pyridostigmine Bromide | 48 | $4,871 |
| Rivastigmine | 27 | $4,516 |
| Ropinirole ErRopinirole Hcl | 19 | $3,422 |
| Selegiline Hcl | 25 | $2,879 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 86 | $2,537 |
| Rasagiline Mesylate | 35 | $2,350 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $191 | $175,23628 claims |
| MDD US Operations, LLCGocovri | $1,760 | $51,59521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 388 neurology providers in Arizona.
Other neurology in Phoenix
- Barry HendinPhoenix$2.3M
- Maria OspinaPhoenix$2.1M
- Suraj MuleyPhoenix$1.7M
- Eric ErossPhoenix$778K
- Steve ChungPhoenix$685K
- Marwan SabbaghPhoenix$603K
- Kerry KnievelPhoenix$509K
- Lori TravisPhoenix$406K
- Jeffrey GittPhoenix$275K
- Todd SchwedtPhoenix$273K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.